HK1062454A1 - Recombinant viral vectors containing the human urokinase plasminogen activator gene and their utilization in the treatment of hepatic fibrosis - Google Patents
Recombinant viral vectors containing the human urokinase plasminogen activator gene and their utilization in the treatment of hepatic fibrosisInfo
- Publication number
- HK1062454A1 HK1062454A1 HK04103987.5A HK04103987A HK1062454A1 HK 1062454 A1 HK1062454 A1 HK 1062454A1 HK 04103987 A HK04103987 A HK 04103987A HK 1062454 A1 HK1062454 A1 HK 1062454A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- utilization
- treatment
- viral vectors
- plasminogen activator
- vectors containing
- Prior art date
Links
- 206010019668 Hepatic fibrosis Diseases 0.000 title 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 title 1
- 239000013603 viral vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA00011713A MXPA00011713A (es) | 2000-11-28 | 2000-11-28 | Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe |
PCT/MX2000/000050 WO2002044393A1 (es) | 2000-11-28 | 2000-11-30 | Vectores recombinantes virales y no-virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipertroficas |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1062454A1 true HK1062454A1 (en) | 2004-11-05 |
Family
ID=32294070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04103987.5A HK1062454A1 (en) | 2000-11-28 | 2004-06-03 | Recombinant viral vectors containing the human urokinase plasminogen activator gene and their utilization in the treatment of hepatic fibrosis |
Country Status (16)
Country | Link |
---|---|
US (1) | US7807457B2 (xx) |
EP (1) | EP1411128B1 (xx) |
JP (1) | JP4733337B2 (xx) |
AR (1) | AR031436A1 (xx) |
AT (1) | ATE409234T1 (xx) |
AU (1) | AU2001217374A1 (xx) |
CA (1) | CA2430367C (xx) |
CY (1) | CY1108667T1 (xx) |
DE (2) | DE60040352D1 (xx) |
DK (1) | DK1411128T3 (xx) |
ES (1) | ES2226597T3 (xx) |
HK (1) | HK1062454A1 (xx) |
MX (1) | MXPA00011713A (xx) |
PT (1) | PT1411128E (xx) |
TR (1) | TR200403256T3 (xx) |
WO (1) | WO2002044393A1 (xx) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1391214A4 (en) | 2001-05-09 | 2006-05-17 | Anges Mg Inc | GM TRANSFER OF ANGIOGENIC FACTOR IN SKIN DISEASES |
WO2007094071A1 (ja) * | 2006-02-17 | 2007-08-23 | Tokyo University Of Agriculture And Technology Tlo Co., Ltd. | 肝機能改善剤 |
ES2791829T3 (es) | 2011-08-26 | 2020-11-06 | Yecuris Corp | Ratas deficientes en fumarilacetoacetato hidrolasa (FAH) e inmunodeficientes y usos de las mismas |
ES2783879T3 (es) * | 2016-01-28 | 2020-09-18 | Accendatech | Dimetilaminomiqueliolida para su uso en el tratamiento de fibrosis pulmonar |
CN109451729B (zh) | 2016-06-08 | 2022-03-22 | 哈佛学院院长及董事 | 工程化病毒载体减少了炎症和免疫反应的诱导 |
CN110191718A (zh) * | 2016-12-15 | 2019-08-30 | 泰伦基国际有限公司 | 一种预防和治疗组织器官纤维化的方法 |
CN108210899A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗组织器官纤维化的药物及其用途 |
US11938172B2 (en) | 2017-06-19 | 2024-03-26 | Talengen International Limited | Method for regulating and controlling GLP-1/GLP-1R and drug |
WO2019094548A1 (en) | 2017-11-08 | 2019-05-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
EP3902913A1 (en) | 2018-12-28 | 2021-11-03 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US5543328A (en) | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
DE4339922C1 (de) | 1993-09-03 | 1994-10-06 | Max Planck Gesellschaft | Vektor für Leber-Gentherapie |
US6686198B1 (en) | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
US5910487A (en) | 1994-12-09 | 1999-06-08 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
US6107027A (en) * | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
US5980886A (en) * | 1994-12-14 | 1999-11-09 | University Of Washington | Recombinant vectors for reconstitution of liver |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US5872154A (en) | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
AU7719596A (en) | 1995-11-07 | 1997-05-29 | Baylor College Of Medicine | Adenovirus-mediated production of bioactive proteins by mammalian cells and animals |
US6020191A (en) * | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
ES2289778T3 (es) * | 1997-04-18 | 2008-02-01 | Biogen Idec Ma Inc. | Proteinas de fusion de la region constante de la inmunoglobulina/receptor tgf-beta tipo ii. |
US5922576A (en) | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
US6436393B1 (en) | 1998-04-29 | 2002-08-20 | Guadalupe Bilbao | Adenoviral vector encoding anti-apoptotic Bcl-2 gene and uses thereof |
-
2000
- 2000-11-28 MX MXPA00011713A patent/MXPA00011713A/es active IP Right Grant
- 2000-11-30 TR TR2004/03256T patent/TR200403256T3/xx unknown
- 2000-11-30 DE DE60040352T patent/DE60040352D1/de not_active Expired - Lifetime
- 2000-11-30 WO PCT/MX2000/000050 patent/WO2002044393A1/es active Application Filing
- 2000-11-30 AU AU2001217374A patent/AU2001217374A1/en not_active Abandoned
- 2000-11-30 US US10/432,989 patent/US7807457B2/en not_active Expired - Fee Related
- 2000-11-30 JP JP2002546741A patent/JP4733337B2/ja not_active Expired - Fee Related
- 2000-11-30 AT AT00980071T patent/ATE409234T1/de active
- 2000-11-30 CA CA2430367A patent/CA2430367C/en not_active Expired - Fee Related
- 2000-11-30 DE DE00980071T patent/DE00980071T1/de active Pending
- 2000-11-30 DK DK00980071T patent/DK1411128T3/da active
- 2000-11-30 EP EP00980071A patent/EP1411128B1/en not_active Expired - Lifetime
- 2000-11-30 ES ES00980071T patent/ES2226597T3/es not_active Expired - Lifetime
- 2000-11-30 PT PT00980071T patent/PT1411128E/pt unknown
-
2001
- 2001-11-28 AR ARP010105552A patent/AR031436A1/es not_active Application Discontinuation
-
2004
- 2004-06-03 HK HK04103987.5A patent/HK1062454A1/xx not_active IP Right Cessation
-
2008
- 2008-12-16 CY CY20081101456T patent/CY1108667T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60040352D1 (de) | 2008-11-06 |
US20040097455A1 (en) | 2004-05-20 |
ES2226597T1 (es) | 2005-04-01 |
US7807457B2 (en) | 2010-10-05 |
AR031436A1 (es) | 2003-09-24 |
AU2001217374A1 (en) | 2002-06-11 |
PT1411128E (pt) | 2008-12-30 |
CA2430367A1 (en) | 2002-06-06 |
EP1411128A1 (en) | 2004-04-21 |
JP2004527224A (ja) | 2004-09-09 |
DE00980071T1 (de) | 2005-03-31 |
WO2002044393A1 (es) | 2002-06-06 |
ES2226597T3 (es) | 2009-03-16 |
CA2430367C (en) | 2012-10-30 |
CY1108667T1 (el) | 2014-04-09 |
JP4733337B2 (ja) | 2011-07-27 |
DK1411128T3 (da) | 2009-02-02 |
TR200403256T3 (tr) | 2005-02-21 |
EP1411128B1 (en) | 2008-09-24 |
MXPA00011713A (es) | 2002-05-31 |
ATE409234T1 (de) | 2008-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0302320A3 (en) | Recombinant constructs and their use in reducing gene expression | |
PL349785A1 (en) | Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant | |
IL153070A0 (en) | Use of baculovirus vectors in gene therapy | |
AU1194802A (en) | DNA expression vectors and methods of use | |
HK1062454A1 (en) | Recombinant viral vectors containing the human urokinase plasminogen activator gene and their utilization in the treatment of hepatic fibrosis | |
IL147969A0 (en) | Peptides that block viral infectivity and methods of use thereof | |
ZA945012B (en) | Viral vectors and their use in gene therapy | |
AU4289100A (en) | Dihydropyrimidines and their use in the treatment of hepatitis | |
EP1148885A4 (en) | ELECTRICALLY INDUCED INCREASE IN IMMUNITY AND EFFECTIVENESS OF IN VIVO DNA VACCINES | |
AU2408002A (en) | Gene HD3A inducing flowering of plant and utilization thereof | |
EP1168918A4 (en) | VACCINE AND GENE THERAPY COMPOSITIONS AND METHOD FOR THEIR PRODUCTION AND USE | |
IL117466A0 (en) | Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy | |
HUP0304092A3 (en) | Combination of active agents with bioregulatory effect and use thereof | |
HK1049860A1 (en) | Recombinant adenoviral vectors and their utillization in the treatment of liver cirrhosis | |
AU2974300A (en) | Plasminogen kringle 4 region fragments and methods of use | |
AU2001264824A1 (en) | Vaccine and gene therapy vector and methods of use thereof | |
ITMI20011138A0 (it) | Vettore e metodi di impiego per l'espressione selettiva di geni in siti di angiogenesi in vivo | |
IL156566A0 (en) | Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis | |
HUP9900045A3 (en) | Improved leukaemic blood-based product and their use in therapy | |
IL155907A0 (en) | Specific promotor of the human vascular endothelial cadherin-2-(hve-cad-2) gene and the therapeutic uses thereof | |
AU5217100A (en) | Adenoviral vectors encoding interferon and their use in gene therapy | |
GB9804674D0 (en) | Therapeutic use of novel peptides in allergy and asthma | |
GB9802359D0 (en) | Therapeutic use of novel peptides in allergy and asthma | |
AU6199100A (en) | Cloning and expressing of human cathepsin k in mammalian cells | |
AU7967901A (en) | Tumour-cell specific gene expression and its use in cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20121130 |